Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

HA-Coated and Non-HA Threads for Midface Lifting and Nasolabial Fold Correction

29 octobre 2026 mis à jour par: Aptos, LLC.

Evaluation of Safety and Effectiveness of APTOS Threads - Absorbable Surgical Sutures Excellence Product Line Models for Mid-face Suspension by Mini-Invasive Surgery to Temporarily Fixate the Cheek Sub-dermis in a Repositioned Site for the Treatment of Moderate to Severe Nasolabial Fold.

This randomized study compared absorbable facial lifting threads with and without a hyaluronic acid (HA) coating in 144 adults with moderate-to-severe nasolabial folds, the lines extending from the sides of the nose toward the corners of the mouth. Participants were randomly assigned in a 1:1 ratio to receive either HA-coated or non-HA threads.

Follow-up continued for six months. The main assessments evaluated adverse events through Day 30 and changes in nasolabial fold severity at Day 90. Independent evaluators assessed standardized photographs, and participants rated their aesthetic improvement and satisfaction. Additional assessments examined safety and maintenance of improvement through Day 180

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Réel)

144

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Batumi, Géorgie, 6000
        • "Total Charm Piazza",15 Vakhtang Gorgasali Street
      • Tbilisi, Géorgie, 0109
        • "Total Charm LTD", Orbeliani Str #18
      • Tbilisi, Géorgie, 0162
        • "Total Charm Vake", 87B Zakaria Paliashvili Street

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

22 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Male and female subjects, 22+ years of age.
  2. Subjects who desire cheek lifting to correct age-related wrinkles in the mid-face as recommended by the treating investigator.
  3. Subject received a rating, in each cheek, by Investigator of at least Grade 3 or Grade 4 for wrinkling of the NLF in the mid-face according to the WSRS.
  4. If a woman is of childbearing potential (not amenorrheic for the previous 24 months or not surgically sterile), then she must have a confirmed negative urine pregnancy test result at screening. If treatment is not provided at the screening visit, a negative urine pregnancy test result is required within 7 days before treatment.
  5. If a woman of childbearing potential (not amenorrheic for the previous 24 months or not surgically sterile), subject confirms she will utilize at least one form of contraception throughout the duration of the study (6 months).
  6. Subjects who are able to understand the study requirements, including the obligation not to receive any other facial procedures or treatments affecting mid-face at any time during the study. These include procedures or treatments done at home or with a professional. Facial treatments include lasers, facial massages, and anything beyond common skincare routine.
  7. Subjects who are willing to participate in the study and to sign a witnessed/informed consent form.
  8. Subjects who are logistically able to present for all study visits and meet all study requirements.
  9. Subjects who are willing to complete a 30-day diary.
  10. Subjects who pass the pinprick and/or cotton swab facial nerve assessment

Exclusion Criteria:

  1. Abnormal rating in mid-face sensation, with inability to feel a 0.4 G monofilament or a cotton wisp at any site on the mid-face.
  2. Active acne or prominent acne scars in the treatment area.
  3. Active inflammatory or infectious conditions.
  4. Allergy or foreign body sensitivities to plastic biomaterials.
  5. Known bleeding disorder.
  6. Breast feeding, pregnant, or not on/willing to use contraception if of childbearing potential (not amenorrheic for the previous 24 months or not surgically sterile).
  7. Known collagen skin disorder.
  8. Pre-existing facial asymmetry.
  9. History of any device use on the mid-face in the prior 6 months (laser, Intense Pulsed Light [IPL], radiofrequency (RF), ultrasound, micro needling, micro needle RF, or cool based treatments).
  10. History of autoimmune or connective tissue disease.
  11. History of facelift, mid-face lift, lower facelift or neck lift that changes the facial structure and anchor points.
  12. History of fat transfer to the mid-face.
  13. History of injectable fillers other than temporary fillers such as HA or Radiesse to the mid-face at any time. Permanent and semi-permanent fillers are not allowed (Poly-L-lactic acids [PLLA], Sculptra).
  14. History of Kybella in the prior 6 months.
  15. History of facial trauma in the mid-face.
  16. History of facial surgical procedures.
  17. Inability to chew, puff cheek, or smile broadly.
  18. Metabolism irregularities.
  19. Receiving immunosuppressive therapy.
  20. Recent weight loss or intention to lose a significant amount of weight during the study period (2 body mass index [BMI] points).
  21. Subjects who have undergone cosmetic facial plastic surgery (with the exception of rhinoplasty or upper blepharoplasty) more than 2 years prior to enrollment, tissue grafting, or tissue lifting or augmentation with any permanent or semi-permanent filler.
  22. Subjects who have had temporary facial dermal filler injections below the orbital rim with HA-based fillers or Radiesse within 18 months, porcine-based collagen fillers within 24 months, or neuromodulator injections to the mid-face or lateral canthal lines, mesotherapy, or resurfacing (laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, chemical peel, or other ablative or non-ablative procedures) within 6 months of entry in the study or who were planning to undergo any of these procedures at any time during the study.
  23. Subjects who have very thin skin in the mid-face region, who have a tendency to accumulate fluid in the lower eyelids, or who have large infraorbital fat pads (i.e., significant convexity or projection from the infraorbital fat pads).
  24. Subjects who have mid-face volume deficit due to congenital defect, trauma, abnormalities in adipose tissue related to immune-mediated diseases such as generalized lipodystrophy (e.g., juvenile dermatomyositis), partial lipodystrophy (e.g., Barraquer-Simons syndrome), inherited disease, or HIVrelated disease.
  25. Subjects who are included to list of vulnerable populations (pediatric, pregnant, elderly individuals with visual or hearing impairments, mentally ill subjects).

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: HA-Coated P(LA/CL) Lifting Threads

Participants received absorbable poly(L-lactide-co-ε-caprolactone) [P(LA/CL)] lifting threads coated with hyaluronic acid in a single bilateral midface procedure under local anesthesia. Five threads were placed subcutaneously on each side of the face. Visage Excellence HA, Visage Excellence Soft HA, or Nano Excellence HA threads were selected according to the planned implantation trajectory. Participants were followed for six months after implantation.

The device consists of absorbable, multibarbed monofilament threads made from poly(L-lactide-co-ε-caprolactone) [P(LA/CL)] and coated with non-animal-derived, non-cross-linked, medium-molecular-weight sodium hyaluronate. Manufactured by Aptos LLC, Georgia, the models used were Visage Excellence HA (190 mm), Visage Excellence Soft HA (100 mm), and Nano Excellence HA (80 mm). All models had the same number of barbs despite their different lengths and were supplied preloaded in cannulas for subcutaneous tissue repositioning.

Expérimental: Non-HA-Coated P(LA/CL) Lifting Threads

Participants received absorbable poly(L-lactide-co-ε-caprolactone) [P(LA/CL)] lifting threads without hyaluronic acid coating in a single bilateral midface procedure under local anesthesia. Five threads were placed subcutaneously on each side of the face. Visage Excellence, Visage Excellence Soft, or Nano Excellence threads were selected according to the planned implantation trajectory. Participants were followed for six months after implantation.

The device consists of absorbable, multibarbed monofilament threads made from poly(L-lactide-co-ε-caprolactone) [P(LA/CL)] without hyaluronic acid coating. Manufactured by Aptos LLC, Georgia, the models used were Visage Excellence (190 mm), Visage Excellence Soft (100 mm), and Nano Excellence (80 mm). All models had the same number of barbs despite their different lengths and were supplied preloaded in cannulas for subcutaneous tissue repositioning.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Délai
Incidence of device and procedure related serious adverse events by Day 30 (Month 1) after the implantation procedure.
Délai: From implantation through Day 30.
From implantation through Day 30.
Reduction in NLF severity at Day 90 (Month 3) after the implantation procedure in comparison with baseline grading, as assessed by blinded evaluators using the Wrinkles Severity Rating Scale (WSRS).
Délai: Baseline and Day 90 after implantation
Baseline and Day 90 after implantation

Mesures de résultats secondaires

Mesure des résultats
Délai
Incidence of all adverse events after implantation of threads throughout the whole study.
Délai: through Day 180 [Month 6] after the implantation procedure
through Day 180 [Month 6] after the implantation procedure
Incidence of early recovery symptoms related to the treatment (threads implantation) among adverse events reported by both patients and treating physician(s)
Délai: Up to Day 14 after the implantation procedure.
Up to Day 14 after the implantation procedure.
Observed values and change from baseline in WSRS
Délai: On Day 30 and Day 180.
On Day 30 and Day 180.
The proportion of subjects with improvement of ≥1 WSRS score at each visit
Délai: Days 30, 90, and 180 after implantation.
Days 30, 90, and 180 after implantation.
Mean GAIS value assessed by blinded evaluators with frequency of each grade and sum of improved subjects (excellent, very much improved, improved)
Délai: On Day 30, Day 90, and Day 180
On Day 30, Day 90, and Day 180
Mean GAIS value assessed by subject with frequency of each grade and sum of improved subjects (excellent, very much improved, improved)
Délai: Days 30, 90, and 180 after implantation.
Days 30, 90, and 180 after implantation.
Patient satisfaction with the procedure outcome assessed using the mean total Face-QTM Satisfaction with Outcome score.
Délai: At Day 30 (Month 1), Day 90 (Month 3), and Day 180 (Month 6) after the implantation procedure.
At Day 30 (Month 1), Day 90 (Month 3), and Day 180 (Month 6) after the implantation procedure.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Les enquêteurs

  • Chaise d'étude: Anna Kadzhaya, MD, Aptos LLC, Tbilisi, Georgia.15 Givi Amilakhvari Street

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

19 juin 2024

Achèvement primaire (Réel)

13 décembre 2024

Achèvement de l'étude (Réel)

1 mars 2025

Dates d'inscription aux études

Première soumission

29 octobre 2026

Première soumission répondant aux critères de contrôle qualité

29 octobre 2026

Première publication (Réel)

4 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

4 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

29 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • Excellence - 001

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner